批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
>>>原始批准或临时批准<<<
| 审批日期 | 提交号 | 审批结论 | 提交分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2010/01/25 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
STANDARD
|
|
|
>>>补充申请<<<
| 审批日期 | 提交号 | 审批结论 | 补充类别或审批类型 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2025/10/14 |
SUPPL-46(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2025/05/28 |
SUPPL-44(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2025/02/12 |
SUPPL-42(补充) |
Approval |
Labeling-Patient Package Insert,Labeling-Container/Carton Labels |
STANDARD
|
|
|
| 2024/11/01 |
SUPPL-43(补充) |
Approval |
Labeling-Medication Guide,Labeling-Package Insert |
901 REQUIRED
|
|
|
| 2023/07/05 |
SUPPL-39(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2022/06/10 |
SUPPL-38(补充) |
Approval |
Labeling-Medication Guide,Labeling-Package Insert |
901 REQUIRED
|
|
|
| 2022/06/10 |
SUPPL-37(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2020/11/20 |
SUPPL-36(补充) |
Approval |
Labeling-Package Insert,Labeling-Medication Guide |
STANDARD
|
|
|
| 2020/08/05 |
SUPPL-35(补充) |
Approval |
Labeling-Medication Guide,Labeling-Package Insert |
STANDARD
|
|
|
| 2019/06/17 |
SUPPL-31(补充) |
Approval |
Efficacy-New Patient Population |
PRIORITY
|
|
|
| 2017/08/25 |
SUPPL-27(补充) |
Approval |
Efficacy-New Indication |
STANDARD
|
|
|
| 2017/07/26 |
SUPPL-29(补充) |
Approval |
REMS - MODIFIED - D-N-A |
N/A
|
|
|
| 2017/04/25 |
SUPPL-28(补充) |
Approval |
Labeling-Medication Guide,Labeling-Container/Carton Labels |
STANDARD
|
|
|
| 2016/09/20 |
SUPPL-26(补充) |
Approval |
REMS-Modified |
N/A
|
|
|
| 2016/04/22 |
SUPPL-25(补充) |
Approval |
Efficacy-Labeling Change With Clinical Data |
STANDARD
|
|
|
| 2015/07/01 |
SUPPL-24(补充) |
Approval |
REMS-Modified |
N/A
|
|
|
| 2015/03/09 |
SUPPL-23(补充) |
Approval |
Labeling-Package Insert |
901 REQUIRED
|
|
|
| 2015/02/25 |
SUPPL-22(补充) |
Approval |
Labeling-Container/Carton Labels |
901 REQUIRED
|
|
|
| 2014/07/31 |
SUPPL-21(补充) |
Approval |
REMS-Modified |
N/A
|
|
|
| 2013/06/13 |
SUPPL-20(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2013/04/16 |
SUPPL-18(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2012/12/13 |
SUPPL-17(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2012/12/03 |
SUPPL-10(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2012/04/06 |
SUPPL-13(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2012/04/06 |
SUPPL-9(补充) |
Approval |
Efficacy-New Indication |
STANDARD
|
|
|
| 2012/04/06 |
SUPPL-7(补充) |
Approval |
Efficacy-Labeling Change With Clinical Data |
STANDARD
|
|
|
| 2011/05/18 |
SUPPL-4(补充) |
Approval |
Labeling-Package Insert,REMS-Modified |
STANDARD
|
|
|
| 2010/12/22 |
SUPPL-1(补充) |
Approval |
Efficacy-Labeling Change With Clinical Data |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
>>>活性成分:LIRAGLUTIDE; 剂型/给药途径:SOLUTION;SUBCUTANEOUS; 规格:18MG/3ML (6MG/ML); 治疗等效代码:AP1<<<
| 申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
| 022341 |
001 |
NDA |
VICTOZA |
LIRAGLUTIDE |
SOLUTION;SUBCUTANEOUS |
18MG/3ML (6MG/ML) |
Prescription |
Yes |
Yes |
AP1 |
2010/01/25
|
NOVO NORDISK INC |
| 215503 |
001 |
ANDA |
LIRAGLUTIDE |
LIRAGLUTIDE |
SOLUTION;SUBCUTANEOUS |
18MG/3ML (6MG/ML) |
Prescription |
No |
No |
AP1 |
2024/12/23
|
HIKMA |
| 218115 |
001 |
ANDA |
LIRAGLUTIDE |
LIRAGLUTIDE |
SOLUTION;SUBCUTANEOUS |
18MG/3ML (6MG/ML) |
Prescription |
No |
No |
AP1 |
2025/04/02
|
NANJING KING FRIEND |
| 215421 |
001 |
ANDA |
LIRAGLUTIDE |
LIRAGLUTIDE |
SOLUTION;SUBCUTANEOUS |
18MG/3ML (6MG/ML) |
Prescription |
No |
No |
AP1 |
2025/07/22
|
LUPIN LTD |